OMER vs ELLO Comparison

Omeros Corp is a United States-based clinical-stage biopharmaceutical company engaged in discovering, developing, and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting immunologic disorders including complement-mediated diseases, cancers, and addictive and compulsive disorders. The drug candidate in the pipeline of complement-targeted therapeutics is narsoplimab (OMS721), a proprietary, patented human monoclonal antibody targeting mannan-binding lectin-associated serine protease 2, the key activator of the lectin pathway of complement. Clinical development of narsoplimab is currently focused on hematopoietic stem cell transplant-associated thrombotic microangiopathy and immunoglobulin nephropathy.

Ellomay Capital Ltd is focused on the utility sector. It is an Israeli public company, which focuses its business in the energy and infrastructure sectors. The company's operating segment includes Photovoltaic power plants (PV Plants); Dorad Energy Ltd. (Dorad); Groen Gas Goor B.V. and a Pumped storage hydro power plant (Manara). It generates maximum revenue from the Dorad segment. Geographically, it derives a majority of its revenue from Spain.